Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model.
A61M 1/16 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang avec membranes
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
A61B 5/0275 - Mesure du débit sanguin utilisant des marqueurs, p.ex. dilution de colorant
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
A61M 1/26 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang avec membranes en mouvement
A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p.ex. adaptation de la température, irradiation
2.
SYSTEM AND METHOD FOR ROBOTIC SURGICAL INTERVENTION IN A MAGNETIC RESONANCE IMAGER
A system and method for image guided assisted medical procedures using modular units, such that a controller, under the direction of a computer and imaging device, can be utilized to drive and track low cost, purpose specific manipulators. The system utilizes modular actuators, self tracking, and linkages. The systems can be optimized at a low cost for most effectively performing surgical procedures, while reusing the more costly components of the system, e.g. the control, driving, and tracking systems. The system and method may utilize MRI real time guidance during the above procedures.
Examples described herein provide a computer-implemented method for training a neural network using forward signal propagation learning. The method includes receiving, at a first layer of the neural network, an input value and a label associated with the input value. The method further includes calculating, for the first layer of the neural network, a first loss value based at least in part on outputs of the first layer for the input value and for the label. The method further includes updating, based at least in part on the first loss value, the first layer of the neural network based at least in part on the outputs of the first layer for the input value and for the label.
G06N 3/063 - Réalisation physique, c. à d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
This disclosure relates to novel C9ORF72 targeting sequences. Novel oligonucleotides for the treatment of neurodegenerative diseases are also provided.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
5.
NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING
Disclosed herein are nanopore tweezer systems that can be used to screen for allosteric inhibitors of protein kinases. In some embodiments, the protein kinase is a mutant kinase that confers resistance to chemotherapeutic drugs during cancer treatment. Therefore, the disclosed systems and methods can be used to identify drugs for treating drug resistant cancers.
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
Novel oligonucleotides that enhance silencing of the expression of a gene containing a single nucleotide polymorphism (SNP) relative to the expression of the corresponding wild-type gene are provided. Methods of using novel oligonucleotides that enhance silencing of the expression of a gene containing a SNP relative to the expression of the corresponding wild-type gene are provided.
A method of forming a flexible electronic component includes treating a flexible fluoroelastomer substrate to increase the surface energy of the substrate to a specified surface energy. After the treatment, a layer of conductive material is printed with an inkjet printer onto the substrate. After the printing, an encapsulant layer comprising a fluoroelastomer is applied onto the substrate.
H05K 1/03 - Emploi de matériaux pour réaliser le substrat
H05K 3/12 - Appareils ou procédés pour la fabrication de circuits imprimés dans lesquels le matériau conducteur est appliqué au support isolant de manière à former le parcours conducteur recherché utilisant la technique de l'impression pour appliquer le matériau conducteur
8.
COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING
The disclosure provides novel methods and compositions for gene editing. In particular, the disclosure relates to compositions and methods of making modified nucleic acid donor templates for highly efficient and precise gene editing.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligature; Utilisation de linkers non fonctionnels ou d'adaptateurs, p.ex. linkers contenant la séquence pour une endonucléase de restriction
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
Aspects of the disclosure relate to compositions and methods for epigenetic regulation of endogenous gene expression from viral vectors. In some embodiments, the disclosure provides expression constructs comprising a viral vector encoding a transgene, the activation of which is regulated by a rapamycin/rapalog-based system, and the transgene is capable of epigenetically regulate an endogenous gene.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A device may (i) at least one electrode associated with an electric generator to generate a pulsed electric field (PEF) in solid tissue, wherein said electrode comprises more than one hole/opening at the end in contact with said solid tissue and an insulating sleeve that can be adjusted to alter the side hole profile. A device may (ii) a cellular-component extraction element by suction through at least one electrode, wherein upon introducing said at least one electrode into said solid tissue, and generating the PEF, the PEF induces a biophysical response from cells in solid tissue or other condition (such as be blood, in vitro etc.) resulting in at least one cellular component to exit to extracellular matrix which is then extracted by said extraction element.
The present invention relates to the construction of and immunization with viral vaccines. In particular, bivalent vaccines that are capable of providing simultaneous virus infection protection for two or more different viruses. Furthermore, the bivalent vaccines contemplated herein are contemplated as being effective in a neonatal mammal. One such bivalent viral vaccine comprises two antigenic epitopes against the dengue viruses and at least one antigenic epitope against hepatitis B virus. Immunization cross-reactivity may also provide infection protection against other viruses as well.
Methods of treating or reducing the risk of obesity and/or obesite-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A system for evaluating a cell sample may comprise a specimen slide scanner, a computer-based image analyzer, and an evaluation subsystem. The specimen slide scanner may be configured to acquire images of an entire surface of a microscope slide upon which the cell sample is mounted. The computer-based image analyzer may be configured to identify one or more follicular clusters within each of the images acquired by the specimen slide scanner. The evaluation subsystem may be configured to (i) compare a number of follicular clusters identified by the computer-based image analyzer to an adequacy threshold, and (ii) present an adequacy notification to a user when the number of the follicular clusters identified by the computer-based image analyzer exceeds the adequacy threshold.
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
A flexible circuit module is disclosed. The flexible circuit module includes a fabric member including a plurality of fibers having non-conductive elements, and conductive elements oriented through the plane of the fabric. Each conductive element includes a first fiber element strand and a first unterminated end opposite the first fiber element strand, and a second fiber element strand having second unterminated end opposite the second fiber element strand. The fabric member further includes a first side with the first fiber element strands extending therefrom and a second side with second fiber element strands extending therefrom. A first hook-and-loop busbar is conductively connected to the first fiber element strands and a second hook-and-loop busbar is conductively connected to the second fiber element strands.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c. à d. le conjugué entier étant un co-médicament, p.ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 5/00 - Médicaments pour le traitement des troubles du système endocrinien
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
18.
METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV)
The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects. In one embodiment, the invention provides a method for immunizing a mammalian subject in need of immunizing against Respiratory Syncytial virus (RSV) infection, comprising, a) providing i) a pre-immune mammalian subject containing RSV neutralizing antibodies, ii) a first composition comprising recombinant chimeric Newcastle disease virus-like particles (ND VLPs), that contain a chimeric protein comprising, in operable combination, 1) stabilized pre-fusion RSV F protein ectodomain, 2) transmembrane (TM) domain of NDV F protein, and 3) cytoplasmic (CT) domain of NDV F protein, and b) administering an immunologically effective amount of the first composition to the pre-immune subject to produce an immunized subject that comprises an increase in the level of the RSV neutralizing antibodies compared to the level of RSV neutralizing antibodies in the pre-immune subject. In one embodiment, the level of the RSV neutralizing antibodies in the pre-immune subject does not prevent RSV infection of the pre-immune subject.
Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (111 1) and methods of treating Huntington's disease using the same.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
Aspects of the disclosure relate to compositions and methods useful for treating ocular ciliopathies, for example Leber congenital amaurosis (LCA). In some embodiments, the disclosure provides isolated nucleic acids comprising a transgene encoding a CEP290 protein fragment, and methods of treating ocular ciliopathies using the same.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
22.
OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
The present disclosure provides a yeast particle delivery system for controlled release of cannabinoids and other hydrophobic payloads. The disclosure further provides methods of making and methods of using the yeast particle delivery system.
The present disclosure provides an improved yeast particle encapsulated nano-silica delivery system. The disclosure further provides methods of making and methods of using a nano-silica yeast particle delivery system.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
This disclosure relates to novel PMS1 targeting sequences. Novel PMS1 targeting oligonucleotides for the treatment of trinucleotide repeat disease or disorder are also provided.
A dispersion includes a plurality of polymer particles, a plurality of inorganic particles, or a combination thereof dispersed in an aqueous solution, wherein the polymer particles, the inorganic particles, or the combination thereof are substantially insoluble in the aqueous solution. At least a portion of the surface of each particle includes one or more functional surfactants disposed on the surface of the particle. The functional surfactants include a C18-32 alkyl group; and at least one functional group that is a sulfonate group, a phosphate group, a ureido group, an acetoacetoxy group, a carboxylate group, a C1-12 fluorocarbon group, a zwitterionic group, a polyether group, a sugar group, a quaternary ammonium group, or a combination thereof. The dispersions can be useful in the preparation of coatings.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
28.
ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE
C07K 16/12 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
A method comprises placing in a vessel a mixture having a specified suspended solids or sludge concentration and comprising a water-based reaction medium and at least one microalgae including filamentous cyanobacteria, said water-based reaction medium comprising a nutrient material that is consumable by a live bacterium or by a live protozoan present in said water-based reaction medium, and incubating said mixture for a specified incubation period under at least intermittent illumination with a specified luminous flux during periods of illumination while mixing said mixture under a specified shear stress, wherein said filamentous cyanobacteria forms a supporting matrix that incorporates said live bacterium or said live protozoan into a biologically-active bioaggregate granule, wherein said incubating produces a plurality of said biologically-active bioaggregate granules.
C02F 3/32 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout caractérisé par les animaux ou végétaux utilisés, p.ex. les algues
C12N 1/12 - Algues unicellulaires; Leurs milieux de culture
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/06 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'introduction de gaz avec agitateur, p.ex. avec agitateur à turbine
A system includes a sensor, a plurality of cells, and a processor. The sensor includes a plurality of transducers arranged on a planar surface and includes a first transducer and a second transducer. The first transducer is configured to produce an analog output signal corresponding to a detected input signal. The cells are arranged in a network and include a first and a second cell and are disposed proximate the sensor in a three-dimensional stacking fashion. The first transducer and the second transducer are electrically coupled to the first cell and the second cell in one-to-one relation. The first cell includes a plurality of inputs and a first cell output. Each input is coupled to an output of a corresponding plurality of neighboring cells. The first cell includes a first memristor and a bridge circuit configured to receive the analog output signal and provide a current corresponding to the detected input signal in a pixel-parallel fashion. The processor is coupled to the network and generates a parameter associated with a weight for each cell of the plurality of cells.
Disclosed herein is a composition that involves a nanopore disposed in a membrane preparation, wherein the nanopore has an outer membrane protein G (OmpG) having 8 to 22 β-strands connected by a plurality of flexible loops on a first side of the membrane preparation and a plurality short turns on a second side of the membrane preparation, wherein a heterologous peptide is inserted within one or more of the flexible loops. Also disclosed herein is a method of detecting binding of a ligand to a target, the method involving: exposing a nanopore composition disclosed herein to a target; assessing a gating pattern of the nanopore; and detecting binding of the target to the heterologous peptide based on the gating pattern.
In some aspects, the disclosure relates to methods for improving titer and yield of viral vector production. In some embodiments, the methods comprise transient silencing of transgene expression during packaging of a viral vector.
This disclosure relates to novel PMS2 targeting sequences. Novel PMS2 targeting oligonucleotides for the treatment of a trinucleotide repeat disease or disorder are also provided.
Droplet-interface bilayer and lipid bilayer membrane compositions stabilized with an amphiphilic polymer are disclosed. Methods of making and using the compositions are also disclosed.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
B01J 13/08 - Coacervation simple, c. à d. addition de substances hautement hydrophiles
35.
METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE DISEASE WITH IPSC-INDUCED HUMAN SKELETAL MUSCLE STEM CELLS
Human skeletal muscle stem cells were generated from facioscapulohumeral muscular dystrophy (FSHD) and healthy control iPSC using a transgene-free skeletal muscle differentiation protocol and production of stable iMyoblasts. Analyses revealed that FSHD and healthy control iMyoblasts are embryonic-like myogenic cells that undergo myotube differentiation ex vivo by growth factor depletion and are efficiently transplantable into the tibialis anterior (TA) muscles of NSG mice, where human muscle under-goes embryonic-to-adult myosin isoform switching. The DUX4 FSHD disease gene maintains its hypomethylated disease state inFSHD iPSC and iMyoblast, and its expression is upregulated during myotube differentiation and in muscle xenografts. Consequently, these iMyoblasts accurately exhibit the molecular pathology of human muscular dystrophies and are useful for the development of drug, gene editing and stem cell therapeutics.
Disclosed herein is a composition comprising a cationically polymerizable first epoxide and a second epoxide. The first epoxide is a glycidyl epoxide and the second epoxide further comprises a glycidyl epoxide and/or a non-glycidyl epoxide. The disclosed composition further comprises an initiator and a filler, where the composition upon external stimulus undergoes an ionic polymerization reaction in a spatially propagating reaction front or in a global reaction that occurs throughout an entire composition.
C08G 59/16 - Polycondensats modifiés par post-traitement chimique par des acides monocarboxyliques ou par leurs anhydrides, halogénures ou esters à bas poids moléculaire
C09J 163/00 - Adhésifs à base de résines époxy; Adhésifs à base de dérivés des résines époxy
C08G 59/68 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les catalyseurs utilisés
37.
METHODS AND COMPOSITIONS FOR RESTORING STMN2 LEVELS
The disclosure relates to compositions and methods for treating a disease or condition associated with a TDP-pathology or a decline in TDP-43 functionality in neuronal cells in a subject, and for identifying candidate agents to suppress or prevent inclusion of an abortive or altered STMN2 RNA sequence.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
38.
DEVELOPMENT OF NOVEL GENE THERAPEUTICS FOR INFLAMMATION-INDUCED BONE LOSS
Aspects of the disclosure relate to compositions and methods for reding inflammation and/or inhibiting bone loss (e.g., bone loss induced by inflammation). In some embodiments, the disclosure provides isolated nucleic acids and expression constructs (e.g., rAAVs, etc.) that encode one or more of the following transgenes: inhibitory nucleic acids targeting Schnurri 3 (SHN3), inhibitory nucleic acids targeting Cathepsin K (CTSK), inhibitory nucleic acids targeting sclerostin (SOST), inhibitory nucleic acids targeting receptor activator of NF-κβ (RANK), inhibitory nucleic acids targeting receptor activator of NF-κβ ligand (RANKL), soluble TNF-α Receptor 2 (sTNFR2), and soluble IL-1 Receptor Antagonist (sIL1Rα). In some embodiments, compositions described by the disclosure are useful for treating diseases associated with inflammation, for example rheumatoid arthritis (RA).
A composition for making a filler including a plurality of ceramic particles, an oxirane monomer in liquid form, an ultraviolet initiator that absorbs ultraviolet, and a thermal initiator.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
41.
NANODEVICES AND METHODS FOR MEASURING BIOFLUIDIC FLOW USING A GRAPHENE-BASED MICROELECTRODE
The invention provides devices and methods for measuring microfluidic flow velocity. The novel electrical nanodevice employs a single microelectrode of monolayer graphene and measures in real time at high resolution and stability microfluidic flow velocity by quantifying contact electrification-induced current variations.
SAMSUNG ELECTRONICS CO., LTD. (République de Corée)
UNIVERSITY OF MASSACHUSETTS (USA)
Inventeur(s)
Han, Seunghoon
Arbabi, Amir
Mcclung, Andrew
Abrégé
An alignment key includes: a first multi-focal meta-lens that includes a plurality of first nanostructures, the plurality of first nanostructures having a first shape distribution that forms two different focal lengths with respect to a first set of regions in the first multi-focal meta-lens; and a second multi-focal meta-lens that includes a plurality of second nanostructures, the plurality of second nanostructures having a second shape distribution that forms the two different focal lengths with respect to a second set of regions in the second multi-focal meta-lens.
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
43.
SELF-REGULATING AAV VECTORS FOR SAFE EXPRESSION OF MECP2 IN RETT SYNDROME
In some aspects, the disclosure relates to compositions and methods of engineering a transgene. In some embodiments, the disclosure provides self-regulating recombinant nucleic acids, viral vectors and pharmaceutical compositions comprising a MeCP2 transgene. In some embodiments, compositions and methods described by the disclosure are useful for treating diseases and disorders associated with a loss of function mutation, for example Rett syndrome.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
In some aspects, the disclosure relates to compositions and methods useful for inhibiting SOD1 expression in cells (e.g., cells of a subject). In some embodiments, the disclosure describes isolated nucleic acids engineered to express an inhibitory nucleic acid targeting endogenous SOD1 and an mRNA encoding a hardened SOD1 protein. In some embodiments, compositions and methods described by the disclosure are useful for treating Amyotrophic Lateral Sclerosis (ALS) in a subject.
This disclosure relates to novel ATN1 targeting sequences. Novel ATN1 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
The present disclosure provides hyperloaded yeast particles. The disclosure further provides methods of making hyperloaded yeast particles and methods of using hyperloaded yeast particles.
A01N 43/80 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec des atomes d'azote et des atomes d'oxygène ou de soufre, comme hétéro-atomes du cycle des cycles à cinq chaînons avec un atome d'azote et soit un atome d'oxygène, soit un atome de soufre, en positions 1,2
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p.ex. peau, os, lait, fibre de coton, coquille d’oeuf, fiel de boeuf ou extraits de plante
A61K 31/085 - Ethers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique
A01N 43/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à plus de six chaînons
Protecting oligonucleotides are provided. Protecting oligonucleotides with 5′ and/or 3′ conjugated moieties are provided. Protecting oligonucleotides with chemical modifications are provided. Methods of using the protecting oligonucleotides for genome editing with a CRISPR nuclease and kits for performing the same are also provided.
The invention provides polymers and polymer-based nano-structures, in particular, polymers and polymer network to which biomolecules (e.g., proteins, antibodies, peptide aptamers) can be covalently conjugated and stably encapsulated therein and be controllably delivered and released upon degradation of the nano-structures in response to specific microenvironment, and compositions and methods of preparation and use thereof.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
49.
SYSTEM AND METHOD FOR AUTO-FLOCCULATION OF WASTEWATER
A method comprises the steps of receiving a wastewater containing solid particles in suspension, agitating the wastewater for a specified agitation period under specified agitation conditions sufficient to enable auto-flocculation of at least a portion of the solid particles into flocs to provide an agitated wastewater, allowing the agitated wastewater to settle for a specified sedimentation period to allow at least a portion of the flocs to settle, and separating at least a portion of the settled flocs from the agitated wastewater to provide a clarified wastewater effluent.
B01F 27/90 - Mélangeurs à agitateurs tournant dans des récipients fixes; Pétrins avec des agitateurs tournant autour d'un axe sensiblement vertical avec des palettes ou des bras
C02F 1/30 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par irradiation
The instant disclosure provides RNA-modulating agents that function to recruit one or more small regulatory RNA molecules (e.g., miRNA molecules, Y RNAs, and siRNAs) to a target mRNA thereby modulating (e.g., inhibiting) the translation of the target mRNA or destabilizing the mRNA. Methods for using the RNA-modulating agents are also provided.
In one aspect, the invention relates to a method of loading exosomes with oligonucleotide cargo, by incubating an oligonucleotide comprising one or more hydrophobic modifications with a population of exosomes for a period of time sufficient to allow loading of the exosomes with the oligonucleotide. Exosomes loaded with hydrophobically modified oligonucleotide cargo, and uses thereof, are also provided.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
This disclosure relates to novel APP targeting sequences. Novel APP targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A method comprises flowing a mixture comprising a water-based reaction medium and at least one microalgae into a reaction vessel, wherein the reaction medium comprises a nutrient material that is consumable by a live microalgae, bacterium, or protozoa present in the reaction medium, incubating the mixture under at least intermittent illumination with a specified luminous flux such that the microalgae forms a supporting matrix that incorporates the live microalgae, bacterium, or protozoa into biologically-active bioaggregate granules, selecting out a first specified portion of the biologically-active bioaggregate granules that are smaller than a first specified size or below a first specified weight or selecting out a second specified portion of the biologically-active bioaggregate granules that are larger than a second specified size or over a second specified weight and removing the first and/or the second specified portions of the biologically-active bioaggregate granules in an effluent stream.
C02F 3/32 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout caractérisé par les animaux ou végétaux utilisés, p.ex. les algues
A plush toy system comprises a plush toy body with an outer fabric layer, wherein the outer fabric layer forms an interactive surface engageable by a user, an array of textile-based pressure sensors coupled to the plush toy body proximate to the outer fabric layer, and sensor conditioning circuits coupled to the plush toy, the sensor conditioning circuits being configured to interpret signals from the textile-based pressure sensors to identify interaction between the user and the interactive surface.
A first method includes detecting, based on sensor data, an environment state; selecting an action based on the environment state; determining an autonomy level associated with the environment state and the action; and performing the action according to the autonomy level. The autonomy level can be selected based at least on an autonomy model and a feedback model. A second method includes calculating, by solving an extended Stochastic Shortest Path (SSP) problem, a policy for solving a task. The policy can map environment states and autonomy levels to actions and autonomy levels. Calculating the policy can include generating plans that operate across multiple levels of autonomy.
B60W 60/00 - Systèmes d’aide à la conduite spécialement adaptés aux véhicules routiers autonomes
B60W 50/00 - COMMANDE CONJUGUÉE DE PLUSIEURS SOUS-ENSEMBLES D'UN VÉHICULE, DE FONCTION OU DE TYPE DIFFÉRENTS; SYSTÈMES DE COMMANDE SPÉCIALEMENT ADAPTÉS AUX VÉHICULES HYBRIDES; SYSTÈMES D'AIDE À LA CONDUITE DE VÉHICULES ROUTIERS, NON LIÉS À LA COMMANDE D'UN SOUS-ENSEMBLE PARTICULIER - Détails des systèmes d'aide à la conduite des véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier
G06N 7/00 - Agencements informatiques fondés sur des modèles mathématiques spécifiques
57.
PROTEIN-POLYMER NANOASSEMBLIES AND INTRACELLULAR PROTEIN DELIVERY
The invention provides novel polymer-protein conjugates and molecular assemblies for controlled intracellular delivery of proteins, and compositions and methods of preparation and use thereof.
C08F 220/28 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle ne contenant pas de cycles aromatiques dans la partie alcool
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A wind turbine system comprises a vessel; a wind turbine mounted to the vessel, the wind turbine comprising rotor blades configured to convert an airstream to rotational shaft power, and an electrical generator configured to convert the rotational shaft power to electrical power; a hydrogen production system configured to be powered by the electrical generator; a propulsion system configured to propel the vessel via power from the electrical generator; and a steering system to control orientation of the vessel relative to the water and the airstream. A method of producing hydrogen comprises floating a vessel in open sea in areas of wind; rotating a wind turbine with the wind to produce electrical energy; synthesizing hydrogen gas from seawater utilizing the electrical energy from the wind turbine; storing the hydrogen gas in a storage system transported by the vessel; and offloading the hydrogen from the storage system.
B63B 1/12 - Caractéristiques hydrodynamiques ou hydrostatiques des coques ou des ailes portantes tirant la portance principalement du déplacement liquide à coques multiples les coques étant reliées rigidement les unes aux autres
F03D 13/25 - Dispositions pour monter ou supporter des mécanismes moteurs à vent; Pylônes ou tours pour des mécanismes moteurs à vent spécialement adaptés à l’installation offshore
F03D 9/32 - Mécanismes moteurs à vent spécialement adaptés à l’installation dans des endroits particuliers sur des objets mobiles, p.ex. des véhicules
B63B 25/12 - Installations de chargement, p.ex. pour le rangement ou l'arrimage; Navires spécialisés à cet effet pour chargement de marchandises fluides fermées
B63H 21/17 - Aménagements de l'appareil moteur de propulsion ou de certains de ses éléments pour utilisation à bord des navires le navire étant actionné par moteurs par moteur électrique
B63H 25/06 - Gouverne; Ralentissement par d'autres moyens que les éléments propulsifs; Ancrage dynamique, c. à d. positionnement des navires au moyen d'éléments de propulsion auxiliaires ou principaux gouvernant par gouvernails
B63H 21/21 - Moyens de commande du moteur ou de la transmission spécialement adaptés à l'utilisation à bord d'un navire
B63B 39/03 - Installations pour diminuer le tangage, le roulis ou autres mouvements similaires indésirables du navire; Appareils pour indiquer l'assiette du navire réduisant les mouvements du navire par déplacement de masses par déplacement de liquides
H02K 7/18 - Association structurelle de génératrices électriques à des moteurs mécaniques d'entraînement, p.ex. à des turbines
H02K 11/00 - Association structurelle de machines dynamo-électriques à des organes électriques ou à des dispositifs de blindage, de surveillance ou de protection
59.
POLYMER NANOPARTICLE, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD FOR INTRACELLULAR DELIVERY OF A CARGO
A polymer nanoparticle includes a crosslinked polymer complex including a cargo encapsulated in a crosslinked polymer network; and a coating on the crosslinked polymer complex. The coating is derived from a cellular membrane. The polymer nanoparticles described herein can advantageously be used to deliver a cargo molecule (e.g., a nucleic acid) to a target location, for example upon administration to a subject in need of therapy.
Embodiments generate medical support text, e.g., assessments and plans, based on patient medical data. One such embodiment begins by receiving medical data for a given patient. Next, a patient knowledge graph for the given patient is generated based on the received medical data and an expanded graph is generated by expanding the patient knowledge graph based upon supplementary data. In turn, the medical support text for the given patient is generated based upon the expanded graph.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
G06F 40/40 - Traitement ou traduction du langage naturel
The present applications discloses an NLS-optimized SpCas9-based prime editor that improves genome editing efficiency exemplified by endogenous loci in cultured cell lines. Using this genome modification system, tumor formation can be initiated through somatic cell editing in the adult mouse. Furthermore, a dual adeno-associated vims (AAVs) is utilized for the delivery of a split-intein prime editor for correction of in vivo pathogenic mutations.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
Aspects of the disclosure relate to compositions and methods for modulating (e.g., inhibiting or promoting) expression of certain mitochondrial regulatory proteins, for example Marf and mitofusin (Mfn). The disclosure is based, in part, on modulation of Marf or Mfn to regulate expression or activity of certain proteins involved in autophagy, for example Vmp1 and vps13D. In some embodiments, compositions and methods described by the disclosure are useful for treating diseases related to aberrant autophagy or mitochondrial function, such as familial neurological movement disorders.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase
This invention relates to treating Myeloproliferative neoplasms (MPNs), specifically Polycythemia Vera (PV). In particular, the invention relates to compositions and methods for inhibiting Polycythemia Vera (PV)-initiating cells, e.g. subsets of hematopoietic stem cells that cause PV symptoms. For one example, Montelukast (e.g., Singulair®) may be used for preventing the development of PV or reducing PV symptoms over long periods of time. Further, Montelukast in combination with other compounds, e.g., JAK2 inhibitor compounds, may also find use for treating patients genetically at risk for developing PV and for PV patients.
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
The disclosure provides a textile having a photothermal absorber layer, which comprises a conjugated polymer; and a transmissive layer, which comprises fibers that forward scatter incident visible light with a transmission of 60% or greater. The photothermal absorber layer can be nylon coated with a conjugated polymer, such as PEDOT. The transmissive layer can be a non-woven polypropylene material. The disclosure also provides wearables, such as a clothing, comprising such textile, and methods for making the same.
D06M 23/06 - Procédés dans lesquels l'agent traitant est dispersé dans un gaz, p.ex. aérosols
B32B 3/28 - Produits stratifiés caractérisés essentiellement par le fait qu'une des couches comporte des discontinuités ou des rugosités externes ou internes, ou bien qu'une des couches est de forme générale non plane; Produits stratifiés caractérisés essentiellement par des particularismes de forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant une feuille mince déformée, p.ex. ondulée, froissée
B32B 5/02 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments
B32B 5/26 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par la présence de plusieurs couches qui comportent des fibres, filaments, grains ou poudre, ou qui sont sous forme de mousse ou essentiellement poreuses une des couches étant fibreuse ou filamenteuse un autre couche également étant fibreuse ou filamenteuse
B32B 5/06 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments caractérisés par une couche fibreuse imbriquée ou cousue avec une autre couche, p.ex. de fibres, de papier
Aspects relate to patterned nanostructures having a feature size not including film thickness of below 5 microns. The patterned nanostructures are made up of nanoparticles having an average particle size of less than 100 nm. A nanoparticle composition, which, in some cases, includes a binder, is applied to a substrate. A patterned mold used in concert with electromagnetic radiation function to manipulate the nanoparticle composition in forming the patterned nanostructure. In some embodiments, the patterned mold nanoimprints a pattern onto the nanoparticle composition and the composition is cured through UV or thermal energy. Three-dimensional patterned nanostructures may be formed. A number of patterned nanostructure layers may be prepared and joined together. In some cases, a patterned nanostructure may be formed as a layer that is releasable from the substrate upon which it is initially formed. Such releasable layers may be arranged to form a three-dimensional patterned nanostructure for suitable applications.
H01B 1/08 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisés; Emploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques oxydes
H01B 3/10 - Isolateurs ou corps isolants caractérisés par le matériau isolant; Emploi de matériaux spécifiés pour leurs propriétés isolantes ou diélectriques composés principalement de substances inorganiques oxydes métalliques
H01B 13/00 - Appareils ou procédés spécialement adaptés à la fabrication de conducteurs ou câbles
H01M 8/124 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte
G02B 1/118 - Revêtements antiréfléchissants ayant des structures de surface de longueur d’onde sous-optique conçues pour améliorer la transmission, p.ex. structures du type œil de mite
H10K 71/20 - Modification de la forme de la couche active dans les dispositifs, p. ex. mise en forme
67.
COMPOSITIONS AND METHODS FOR TREATMENT OF ACUTE LIVER FAILURE
Aspects of the disclosure relate to isolated nucleic acids encoding one or more inhibitory nucleic acids. In some embodiments, the inhibitory nucleic acids are microRNAs (miRNAs) or artificial microRNAs (amiRNAs). The inhibitory nucleic acids may target one or more genes involved in cytochrome p450 toxicity, for example Slc16a2, Acls5, and Cyb5b. In some embodiments, an inhibitory nucleic acid is a miR-375. The disclosure relates, in some aspects, to methods of reducing cytochrome p450-related toxicity in a cell (e.g., a liver cell) by administering the isolated nucleic acids of the disclosure.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
68.
DCAS13-MEDIATED THERAPEUTIC RNA BASE EDITING FOR IN VIVO GENE THERAPY
Aspects of the disclosure relate to compositions (e.g., isolated nucleic acids, rAAV vectors, rAAVs, etc.) and methods for gene editing. The disclosure is based, in part, on isolated nucleic acids encoding combinations of gene editing proteins (e.g., Cas proteins) and base editors (e.g., Adenosine Deaminase Acting on RNA deaminase domains) with certain regulatory sequences that are amenable to packaging in recombinant adeno-associated viruses (rAAVs). In some embodiments, compositions described by the disclosure are useful for treating certain diseases in a subject in need thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
This disclosure relates to novel MECP2 targeting sequences. Novel MECP2 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
70.
ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF
Aspects of the disclosure relate to compositions and methods for expressing anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (e.g., AAV2 variants, AAV2/3 hybrid variants, AAV8 variants, etc.), and a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
This disclosure relates to novel MLH1 targeting sequences. Novel MLH1 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Energy harvesting devices and methods are provided. An energy harvesting device includes an adsorption layer comprising a nanoporous material and at least two electrodes in operative arrangement with the adsorption layer. The nanoporous material comprises a nonbiological nanoporous material, a nonprotein biological nanoporous material, or a combination thereof. The adsorption layer and at least two electrodes are configured to generate a voltage differential on exposure of the adsorption layer to ambient moisture.
The present disclosure presents biosensor devices, systems, and related methods. One such biosensor device comprises a substrate; a semiconductive channel member suspending between a pair of contacts on the substrate, wherein the semiconductive channel member comprises a convex protruding channel structure; and wherein the convex protruding channel structure is configured to detect both electrical and mechanical cellular responses. Other devices, systems, and methods are also presented.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A zwitterion has a structure according to the Formula
A zwitterion has a structure according to the Formula
A zwitterion has a structure according to the Formula
wherein Z, L1, L2, R, Y, and x are as defined herein. The zwitterions can be used to provide the corresponding polymer zwitterions, for example using free radical polymerization techniques.
Various aspects disclosed relate to a redox flow battery that includes an anode in communication with a current collector and comprising a first solid charge storage medium disposed within the anode. The redox flow battery further includes a cathode in communication with the current collector and comprising a second solid charge storage medium disposed within the cathode. At least one of the anode, current collector, or cathode includes a complex having a structure according to Formula I:
Various aspects disclosed relate to a redox flow battery that includes an anode in communication with a current collector and comprising a first solid charge storage medium disposed within the anode. The redox flow battery further includes a cathode in communication with the current collector and comprising a second solid charge storage medium disposed within the cathode. At least one of the anode, current collector, or cathode includes a complex having a structure according to Formula I:
[ML2]m−2[CAT]n+2 (I),
wherein,
M is metal;
L is a ligand.
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 8/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible à régénération, p.ex. batteries à flux REDOX ou éléments à combustible secondaires
76.
LOW-K AND LOW DIELECTRIC LOSS DIELECTRIC COMPOSITION FOR AEROSOL JET PRINTING
A printable dielectric ink composition includes an inhibited catalyst-polymer complex and a crosslinker, wherein the printable dielectric ink composition has a viscosity of about 1 to about 10 cP.
C09D 11/101 - Encres spécialement adaptées aux procédés d’imprimerie mettant en œuvre la réticulation par énergie ondulatoire ou par radiation de particules, p.ex. réticulation par UV qui suit l’impression
C09D 11/03 - Encres d’imprimerie caractérisées par des particularités autres que la nature chimique du liant
The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 38/50 - Hydrolases (3) agissant sur des liaisons carbone-azote autres que des liaisons peptidiques (3.5), p.ex. asparaginase
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
78.
NANOPORE-MATCHED PROTEIN SHUTTLE FOR MOLECULAR CHARACTERIZATION
Systems and methods are provided for trapping and electrically monitoring molecules in a nanopore sensor. The nanopore sensor comprises a support structure with a first and a second fluidic chamber, at least one nanopore fluidically connected to the two chambers, and a protein shuttle. The protein shuttle comprises an electrically charged protein molecule, such as Avidin. The nanopore can be a Clytosolin A. A method can comprise applying a voltage across the nanopores to draw protein shuttles towards the nanopores. The ionic current through each or all of the nanopores can be concurrently measured. Based on the measured ionic current, blockage events can be detected. Each blockage event indicates a capture of a protein shuttle by at least one nanopore. Each blockage event can be detected through a change of the total ionic current flow or a change in the ionic current flow for a particular nanopore.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
79.
USE OF NOVEL MIRNA-BINDING SITE CASSETTES FOR ANTIGEN-PRESENTING CELL DETARGETING OF TRANSGENE EXPRESSION BY RAAV GENE THERAPY
The disclosure, in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.
A system and method for memory allocation and management in non-uniform memory access (“NUMA”) architecture computing environments is disclosed. The system and method contemplates both hardware heterogeneity and allocation/deallocation attributes, with fine-grained memory management. NUMAlloc is centered on a binding-based memory management. On top of it, NUMAlloc proposes an “origin-aware memory management” to ensure the locality of memory allocations and deallocations, as well as a method called “incremental sharing” to balance the performance benefits and memory overhead of using transparent huge pages. It further introduced an interleaved heap to reduce the load imbalance among different nodes and an efficient mechanism for object movement. The system and method provides a scalable and increased performance alternative over other prior art memory allocators.
A composition includes a plurality of lead halide perovskite nanocrystals and an ammonium halide-containing copolymer or a guanidinium halide-containing copolymer. The ammonium halide-containing copolymer and guanidinium halide-containing copolymer can include repeating units defined herein. The composition can be particularly useful for color tuning perovskite nanocrystals, and can be well-suited for light emitting applications, including light emitting diodes.
C09K 11/66 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
H10K 50/115 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL] comprenant des nanostructures inorganiques actives, p. ex. des points quantiques luminescents
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p.ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
An air scrubber/purifying filter includes filter material having a substrate, an adhesive coating applied to the substrate and a plurality of flock fibers flocked into the adhesive coating. In one embodiment, bi-component flock fibers are flocked on a Reticulated Foam (RF) substrate and subsequently fibrillated. In another embodiment, Cross-Flow Flock Fiber (CFF) filter material includes edgewise, cross cut, bonded, stacked fabric layers such that the passage of air through the flock fibers is normal to the flock fiber orientation. In some embodiments the flock fibers are coated with biocidal, virucidal and/or metalized coatings or finishes to provide biocidal or virucidal properties to the filter media.
Various examples are provided related to high-speed autofocus control. In one example, a method includes obtaining a first image of a target with a camera; adjusting focus of the camera by a specified AF bin step size; obtaining a second image of the target; adjusting focus of the camera by the specified AF bin step size; obtaining a third image of the target; determining an optimal focus using data of the second and third images; and adjusting focus of the camera to the optimal focus. In another example, a method includes generating an input vector comprising a sequence of input-output pairs associated with a piezoelectric controlled motion stage that can position a camera relative to a target; determine a control input for the motion stage using a LSTM backpropagation network trained to minimize a cost function over a defined prediction horizon; and applying the control input to the motion stage.
This disclosure relates to novel MLH3 targeting sequences. Novel MLH3 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
The present invention relates to a negative pressure wound closure system and methods for using such a system. Preferred embodiments of the invention facilitate closure of the wound by preferentially contracting to provide for movement of the tissue. Preferred embodiments can utilize tissue securing portions that aid in securing the invention within a wound.
A61F 13/00 - Bandages ou pansements; Garnitures absorbantes
A61M 1/00 - Dispositifs de succion ou de pompage à usage médical; Dispositifs pour retirer, traiter ou transporter les liquides du corps; Systèmes de drainage
The present disclosure provides antisense compounds, methods, and compositions for silencing C9ORF72 transcripts. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with C9ORF72 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with C9ORF72.
In some aspects, the disclosure relates to compositions and methods for treating fibrodysplasia ossificans progressiva (FOP) in a subject. In some aspects, the disclosure provides isolated nucleic acids, and vectors such as rAAV vectors, configured to express transgenes that inhibit (e.g., decrease) expression of mutated AVCR1 gene in muscle cells or connective tissues.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget
Disclosed herein is a foam composition comprising a first epoxide comprising a first glycidyl epoxide and/or a first non-glycidyl epoxide; a second epoxide comprising a second glycidyl epoxide and/or a second non-glycidyl epoxide; wherein the first glycidyl epoxide is different from the second glycidyl epoxide and wherein the first non-glycidyl epoxide is different from the second non-glycidyl epoxide; wherein the first and the second epoxide are cationically polymerizable; an initiator; and a diluent; wherein the diluent is present in about 0.1 to 30 wt %, based on the total weight of the composition; wherein the composition upon external stimulus undergoes an ionic polymerization reaction in a spatially propagating reaction front or in a global reaction that occurs throughout an entire composition.
A bodily fluid absorbing, fiber flocked modular medical swab includes a prefabricated pre-flocked tip having a pre-flocked braided yarn hollow tube; a pre-flocked hollow plastic tube; a pre-flocked fabric; a pre-flocked yarn band or a pre-flocked narrow fabric band/tape/ribbon base. A swab rod is attached to the pre-flocked tip.
A61F 13/38 - Tampons comportant une poignée en forme de bâtonnet, p.ex. bâtonnets ouatés
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
90.
DNA-BINDING DOMAIN TRANSACTIVATORS AND USES THEREOF
In some aspects, the disclosure relates to recombinant adeno-associated viruses (rAAVs) comprising a nucleic acid encoding a fusion protein comprising a DNA-binding domain and a transcriptional regulator domain and methods of using the same. In some embodiments, expression of the fusion protein results in modified expression of a target gene in a cell.
Described herein are synthetic methods for producing sequence-specific RNA oligonucleotides that eliminate impurities produced in prior art methods. In one aspect, an end-protected capture DNA complementary to a portion of the product RNA is employed. In another aspect, the template DNA is covalently or noncovalently linked to the RNA polymerase, either directly or through the use of a nontemplate DNA. In a third aspect, a flow chamber is employed. All of the methods can be used in combination.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6865 - Amplification à base de promoteurs, p.ex. amplification de séquence d’acide nucléique [NASBA], système de réplication de séquence auto-entretenue [3SR] ou d’amplification à base de transcription [TAS]
92.
SILENCING OF DUX4 BY RECOMBINANT GENE EDITING COMPLEXES
The disclosure relates to methods and compositions for regulating expression of DUX4. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy. FSHD).
A method of making a meat structured protein product includes combining a denatured plant protein and a polysaccharide in the presence of an aqueous solvent to provide a phase-separated mixture including a dispersed phase rich in polysaccharide and a continuous phase rich in the denatured plant protein. The method further includes forming fibrous structures of the polysaccharide in a protein matrix of the plant protein at a temperature of less than 100° C. The protein matrix can be crosslinked to provide the meat structured protein product. Meat structured protein products made by the method are also disclosed.
The Board of Trustees of the University of Maine System (USA)
Inventeur(s)
Schiffman, Jessica Deborah
Howell, Caitlin Lake
Shah, Rushabh Manish
Abrégé
A liquid infused membrane includes a porous fluorine-containing polymer membrane and a perfluoropolyether oil coating on at least a portion of the first surface and at least a portion of the pore wall. Advantageously, the liquid infused membrane does not exhibit gating. Methods for the manufacture thereof and uses of the liquid infused membrane are also disclosed.
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétés; Procédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
Described herein are compositions and methods for treating inflammation, and inflammation-related conditions, using fumarate or fumarate analogs or inhibitors of fumarate hydratase (FH).
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p.ex. piracétam, éthosuximide
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A unique point absorber type wave energy conversion device is disclosed that includes a Power Take Off (PTO) which uses a torsion spring to return a vertical shaft to its original position after being rotated by a rope or cord that pulls a reel via a guide system. This spring return allows the PTO and housing to stay stationary under the wave energy while a buoy at the surface provides an oscillating linear movement. The oscillating rotary motion caused by the interaction of the buoy and spring is converted into a one directional motion via a one-way clutch and is transmitted to generators using a gearbox that increases rotational speed.
F03B 13/18 - Utilisation du mouvement relatif entre un élément déplacé par les vagues et un autre élément l'autre élément étant fixé, à au moins un point, par rapport au fond ou au bord de la mer
F03B 13/16 - Utilisation du mouvement relatif entre un élément déplacé par les vagues et un autre élément
97.
METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED MACULAR
DEGENERATION
Aspects of the disclosure relate to methods and compositions for treatment of certain ocular diseases and disorders, for example age-related macular degeneration (AMD). In some embodiments, the methods comprise administering a subject having AMD one or more therapeutic agents that modulate the mTORCl pathway (or a component thereof). The disclosure is based, in part, on methods for treating AMD in a subject by administering one or more kinase inhibitors, for example one or more serine/threonine kinase inhibitors. In some embodiments, at least one of the serine/threonine kinase inhibitors is a Ribosomal protein S6 kinase beta-1 (S6K1) inhibitor.
A61K 31/202 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p.ex. acide linolénique
Compositions comprising metal entities in combination with an activating agent, or pharmaceutically acceptable salts thereof are disclosed. Certain compositions are active as antibacterial, antiviral, antifungal, anti-protozoal, and/or anti-worm agents. The disclosure provides pharmaceutical compositions containing the compositions. Methods of using the composition to treat bacterial infections are disclosed.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
In one embodiment, the present invention provides an intrauterine device (IUD) comprising an oval shape, wherein the device comprises a core of magnetic material, an inert material or copper coating the core, wherein the coating comprises a pharmaceutical agent, copper or a combination thereof. Another embodiment provides a method to suppress estrus in a subject comprising inserting an intrauterine device (IUD) comprising an oval shape, wherein the device comprises a core of magnetic material and an inert material or copper coating the core.
The present invention relates to genomic analysis. In particular, the present invention provides methods and compositions for mapping genomic interactions.
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN